<DOC>
	<DOCNO>NCT01877239</DOCNO>
	<brief_summary>This prospective non-interventional observational study evaluate treatment moderately active RA patient every day clinical practice Austria . Patients observe 52 week . The primary endpoint percentage patient reach CDAI remission 24 week .</brief_summary>
	<brief_title>Study Observe Safety Efficacy Etanercept ( Enbrel® ) Patients With Moderately Active Rheumatoid Arthritis Every Day Clinical Practice Austria</brief_title>
	<detailed_description>Non-interventional observational study , national , multicenter prospective non-interventional study ( NIS ) define Austrian Drug Law § 2a Section 3 N/A</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . The patient eligible receive Etanercept treatment accord Austrian SmPC . 2 . The decision treat patient Etanercept make independently physician clearly separate decision include patient study . The treatment decision make advance dependent protocol . 3 . The patient inform study give his/her consent sign Independent Ethics Committee ( IEC ) submit write Informed Consent form use data . 4 . The patient moderately active RA , define disease activity CDAI &gt; 10 ≤22 and/or DAS28 ( CRP ) &gt; 3.2 ≤ 5.1 1 . Any contraindication accord Austrian SmPC , include : A hypersensitivity component Etanercept , active tuberculosis serious infection . 2 . Patient previously participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>